Spleen Radiotherapy Decreases Severe CIT in Advanced NSCLC (SPLEENIR)

Inclusion Criteria: 1. Patients with advanced (Stage IIIA or IIIB AJCC 7) NSCLC that was histologically or cytologically inoperable 2. ECOG whole body status (performancestatus,PS) level 0 or 1 3. The estimated survival time is more than 12 weeks, 18 \~75 years old 4. Laboratory results within 2 weeks prior to radiotherapy met the following criteria: ① Neutrophil count \> 1,500/ MCL Heathko-Pilot Oncology Research Fund; ② Platelet \> 50,000/ MCL; ③ Total bilirubin \< 1.5 times of the normal upper limit value; ④AST(SGOT)/ALT(SGPT) \< 2.5 times of the normal upper limit; ⑤ Serum creatinine \< 1.5 times of the normal upper limit value; ⑥ The results of coagulation function examination were within the normal range 5. Women of childbearing age must have taken reliable contraceptive measures or conducted pregnancy tests (serum or urine) within 7 days before admission, and the results are negative, and are willing to use appropriate methods of contraception during the trial period and 8 weeks after the last administration of the trial drug. For men, they must agree to use appropriate methods of contraception or surgical sterilization during the trial period and 8 weeks after the last administration of the trial drug 6. Understand and voluntarily sign written informed consent 7. The investigator judged that the patient had good compliance Exclusion Criteria: 1. Patients with serious functional damage of important organs; 2. Patients diagnosed adequately with other malignant tumors; 3. Pregnant or lactating women; 4. Patients in an active period of acute or chronic infectious diseases; 5. Combined with the disease of connective tissue 6. Patients who are allergic to any drugs or people with allergies; 7. Patients who participate in other clinical trials concurrently; 8. Brain metastases without being controlled; 9. With immunologic thrombocytopenia； 10. Excluding thrombocytopenia caused by other reasons(Non chemotherapeutic agents, such as heparin, etc.); 11. The degree of tumor thrombus \>2; 12. Patients who are considered not eligible for the trial after evaluation by investigator.